Eli Lilly reports positive phase 3 trial results for Covid antibody drug

Eli Lilly’s combination antibody drug produced more positive results treating Covid-19 in phase 3 trials, CNBC’s Meg Tirrell reports. The therapeutic was found to reduce the risk of hospitalization and death by 87% in the study of more than 750 high-risk patients.

The combination drug was granted emergency use authorization from the Food and Drug Administration in February. The latest study found a lower dose produced superior results.

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.


Connect with CNBC News Online

#CNBC
#CNBCTV